# Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

> **NCT00761345** · PHASE1 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 27 (actual)

## Conditions studied

- Pancreatic Carcinoma Non-resectable
- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** Erlotinib
- **RADIATION:** low dose fractionated radiotherapy

## Key facts

- **NCT ID:** NCT00761345
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2014-07
- **Final completion:** 2015-02
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761345, "Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT00761345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*